Update on the Diagnosis and Management of Acute Colonic Pseudo-obstruction (ACPO).
Acute Colonic Pseudo-obstruction
Large bowel dilation
Pseudo-obstruction
Journal
Current gastroenterology reports
ISSN: 1534-312X
Titre abrégé: Curr Gastroenterol Rep
Pays: United States
ID NLM: 100888896
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
09
07
2023
medline:
10
8
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
ppublish
Résumé
Acute Colonic Pseudo-obstruction (ACPO) is a cause of large intestinal dilation and obstruction without any physical transition point. It remains difficult to diagnose and treat. We review the recent updates on diagnosis and management of ACPO. Recent guidelines have posited that conservative management can be tried in most cases of ACPO, but that early decompression and surgery should be considered. Use of neostigmine is still a viable option but there is also promising data on pyridostigmine as well as prucalopride. Resolution of ACPO should be followed by daily use of polyethylene glycol (PEG) to help prevent recurrence. ACPO warrants early and accurate diagnosis with exclusion of alternate causes of large bowel dilation. Conservative management can be attempted for 48-72 h in those with cecal diameters < 12 cm and without signs of peritonitis and perforation. Early escalation of management should be attempted with neostigmine followed by endoscopy and/or surgery as needed, given that longer periods of dilation are associated with worse outcomes. There is promising new evidence for use of pyridostigmine and prucalopride, but further trials are needed prior to incorporating them into regular use. Finally, studies are lacking regarding prevention of ACPO after initial resolution.
Identifiants
pubmed: 37486594
doi: 10.1007/s11894-023-00881-w
pii: 10.1007/s11894-023-00881-w
doi:
Substances chimiques
Neostigmine
3982TWQ96G
Polyethylene Glycols
3WJQ0SDW1A
Pyridostigmine Bromide
KVI301NA53
Cholinesterase Inhibitors
0
Parasympathomimetics
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
191-197Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.